SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the pricing of its initial public offering of 8,333,334 shares of its common stock at an initial public offering price of $14.00 per share.

加利福尼亚州南旧金山，2026年10月8日（环球电讯社）——专注于组织调节性T细胞（Treg）生物学以发现和开发免疫调节药物的临床阶段生物技术公司TRex Bio, Inc.（“TRexBio”）（纳斯达克股票代码：TRXB）今日宣布，其首次公开发行8,333,334股普通股，发行价为每股14.00美元。

All of the shares are being offered by TRexBio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $116.7 million. TRexBio’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 9, 2026, under the ticker symbol “TRXB”.

所有股份均由TRexBio发售。在扣除承销折扣、佣金及其他发行费用之前，本次发行的预计总收益约为1.167亿美元。TRexBio的普通股预计将于2026年10月9日在纳斯达克全球精选市场开始交易，股票代码为“TRXB”。

The offering is expected to close on October 13, 2026, subject to the satisfaction of customary closing conditions. In addition, TRexBio has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions..

本次发行预计将于2026年10月13日完成，但须满足惯常的交割条件。此外，TRexBio已授予承销商一项为期30天的选择权，可按首次公开发行价格扣除承销折扣和佣金后的净额，额外购买最多1,250,000股普通股。

J.P. Morgan, Evercore ISI, Cantor, and Stifel are acting as lead book-running managers for the offering. Wedbush PacGrow is acting as book-running manager for the offering.

摩根大通、Evercore ISI、坎托尔和斯蒂费尔担任此次发行的牵头账簿管理人。韦德布什·帕克格罗担任此次发行的账簿管理人。

A registration statement (File No. 333-299018) relating to the shares being sold in the offering has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on October 8, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: J.P.

与本次发行中出售的股份相关的注册声明（文件编号：333-299018）已提交至美国证券交易委员会（“SEC”），并于2026年10月8日生效。本次发行仅通过招股说明书进行。最终招股说明书的副本在备妥后，可从以下机构获取：J.P.

Morgan Securities LLC, Attention Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; and Evercore Group L.L.C., 55 East 52nd Street, 35th Floor, New York, New York 10055, Attention: Equity Capital Markets, or by email at ecm.prospectus@evercore.com or by telephone at (888) 474-0200..

摩根证券有限责任公司（收件人：Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717），或通过电子邮件发送至 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；以及 Evercore Group L.L.C.（地址：55 East 52nd Street, 35th Floor, New York, New York 10055，收件人：股票资本市场部），或通过电子邮件发送至 ecm.prospectus@evercore.com，或通过电话 (888) 474-0200 联系。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或购买要约的招揽，也不得在任何州或司法管辖区进行这些证券的要约或销售，如果在该等州或司法管辖区，此类要约、招揽或销售在根据该州或司法管辖区的证券法进行注册或资格认定之前是非法的。

About TRexBio

关于 TRexBio

TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio’s Deep Biology Platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts.

TRexBio 是一家处于临床阶段的生物技术公司，专注于组织驻留调节性T细胞（Treg）生物学研究，致力于发现和开发免疫调节药物，旨在恢复免疫平衡并促进组织修复，以满足自身免疫性和炎症性疾病患者尚未被满足的医疗需求。TRexBio 的 Deep Biology 平台解码人体组织中 Treg 的功能，绘制免疫失调的关键驱动因素图谱，并揭示新的靶点和见解，为药物发现及转化研究提供指导。

This platform has generated multiple therapeutic development candidates across TRexBio’s wholly owned pipeline and through collaborations with leading pharmaceutical partners. TRexBio is led by an experienced management team and headquartered in South San Francisco, California..

该平台已在TRexBio全资拥有的产品管线中，并通过与领先制药合作伙伴的合作，生成了多个治疗性开发候选药物。TRexBio由经验丰富的管理团队领导，总部位于加利福尼亚州南旧金山。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the completion, timing, and size of the initial public offering and the commencement of trading on the Nasdaq Global Select Market.

本新闻稿包含前瞻性陈述。提醒投资者不要过度依赖这些前瞻性陈述，包括有关首次公开发行的完成、时间安排和规模，以及在纳斯达克全球精选市场开始交易的陈述。

Each forward-looking statement is subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms described or at all. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of TRexBio, including, without limitation, market conditions, failure of customary closing conditions, and the factors discussed in the “Risk Factors” section of the prospectus that forms a part of the registration statement, in the form last filed with the SEC.

每项前瞻性陈述均受限于预测未来结果和状况时固有的不确定性，无法保证上述首次公开发行将按所述条款完成或根本不会完成。拟议的首次公开发行的完成及其条款受多种因素影响，其中许多因素超出 TRexBio 的控制范围，包括但不限于市场状况、常规交割条件未能满足，以及作为注册声明一部分的招股说明书（以最近向美国证券交易委员会提交的版本为准）中“风险因素”一节所讨论的因素。

These forward-looking statements speak only as of the date of this press release and TRexBio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise..

这些前瞻性陈述仅截至本新闻稿发布之日有效，TRexBio 不承担因新信息、未来事件或其他原因而公开更新或修订任何前瞻性陈述的义务。